Latest Atazanavir Campaign News

August 27, 2015 - Entrevista a Mario Rios de Justicia en Salud en el programa Exitosa Noticias

August 27, 2015 - Entrevista a Mario Rios de Justicia en Salud en el programa San Borja Noticias

August 22, 2015 - La Republica: PJ ordena al Minsa informar sobre licencia para Atazanavir

July 14, 2015 - La Republica: Licencia obligatoria hubiera permitido 75% de ahorro en Atazanavir

July 13, 2015 - La Republica: Bristol rebaja en 35% precio de fármaco contra el VIH, pero no deja el monopolio

July 13, 2015 - Bolsamania: Antirretroviral Atazanavir cuesta 35% menos hoy que ayer pero aún es muy caro en Perú

May 21, 2015 - Wall Street Journal: Bristol-Myers Faces a Compulsory License for an AIDS Drug in Peru

April 28, 2015 - Public Citizen and IFARMA letter to INDECOPI on compulsory licensing

April 28, 2015 - Civil society letter to Peruvian officials on atazanavir compuslory license (available in English here)

April 28, 2015 - Academics letter to Peruvian officials on atazanavir compuslory license (available in English here)

April 21, 2015 - Agenda Politica - Peruvian Minister of Health Anibal Velasquez on atazanavir compulsory license

April 9, 2015 - Patentes dadas por Indecopi a fármacos afectan a la salud pública

March 3, 2015 - Laboratorio presiona para conservar patente que costará a peruanos 130 millones de soles

November 17, 2014 - Letter sent to President Ollanta Humala of Peru requesting a compulsory license on the HIV medication atazanavir in Peru

November 17, 2014 - Letter sent to Ministry of Health of Peru requesting a compulsory license on the HIV medication atazanavir in Peru

August 14, 2014 - - Sobregasto en medicamentos (en español)

June 19, 2014 - Patente en ARV: Caso atazanavir (courtesy of Javier Llamoza; en español)

April 17, 2014 - Peruvian Civil Society Organizations Demand that Government Issue a Compulsory License for Atazanavir (links to

October 31, 2013-The Economic Times: Patent office rejects BDR Pharma's compulsory licensing application

August 6, 2013:
Kractivism: Press Release- Campaign for Affordable Trastuzumab (links to

August 5, 2013 -
Bio World: China Revokes Viread Patent; Pricing Was at Issue (links to

May 30, 2013- The Jakarta Globe: Future Hepatitis C Blockbusters May Spawn Compulsory Generics (links to

March 18, 2013-
ACTION! Essential Inventions issues request for non-voluntary authorization to use patents under Article 14 of Greece patent law (links to

March 17, 2013-Financial Times: Athens urged to import generic drugs (links to

December, 2012
Secondary Patenting: A Threat to Affordable Generic Patenting by I-MAK

November 2, 2012- Nature: NIH asked to grant open license on HIV drug (links to

Compulsory Licenses and Right to Health Litigation

Compulsory Licensing

Crucial right of countries for expanding access to medicines

Countries may exercise their right to issue compulsory licenses to expand access to medicines that are still protected by patents. A compulsory license is a special mechanism that authorizes a government to introduce generic competition for a patented product in exchange for royalty payments to the patent holder. Various countries have issued compulsory licenses on to expand patient access to medicines, ranging from HIV to cancer treatments. Unfortunately, due to various international and domestic pressures, this right is under-utilized by countries whose citizens would benefit.

Litigating the right to health

Human rights law and its relationship to intellectual property protection and access

More than 100 countries have incorporated a right to health into their constitutions, and 160 have acceded to this right through their international treaty obligations. And, in the last fifteen years, domestic courts have gone far to safeguard this right: courts have not only granted plaintiffs access to specific medications, but also commanded governments to make particular medications available to all citizens. More recently, domestic courts have also displayed a growing willingness to use human rights laws to reinterpret and even strike down IP laws that impede access to medications.

Kaletra Campaign

A worldwide campaign to expand access to a vital HIV treatment

On November 10, 2011, public health groups in a dozen countries launched a global campaign to challenge Abbott Laboratories’ monopolistic hold on Kaletra (lopinavir+ritonavir), a critical HIV/AIDS medicine. The goal was to spur competition by generic drugmakers and thereby lower the medicine’s price, as well as to free up its components for new and improved combination treatments. The campaign comprises an unprecedented global effort to fight Big Pharma’s political power and improve access to lifesaving medicines.

Atazanavir Campaign in Peru

A campaign to obtain a compulsory license on an important and expensive HIV medication in Peru

On November 17, 2014, public health activists in Peru sent a letter to the Peruvian president, Ollanta Humala, and the Peruvian Ministry of Health requesting that the president issue a compulsory license on atazanavir, an important, second-line HIV drug on which Bristol-Myers Squibb currently holds patents in Peru. The grant of a compulsory license on this medication would save the Peruvian government 26 million nuevo soles (roughly USD $9 million) in 2015 alone. Furthermore, the grant of this license could save Peru about USD $44 million over the course of the next few years, until Bristol-Myers Squibb’s expires in 2019.

Nevertheless, a recent article in Peru’s La Republica newspaper indicates that Minister of Health, Aníbal Velásquez, has actually signed a decree declaring atazanavir to be in the public interest and issuing a compulsory license on the patents associated with atazanavir. The article reported that this decree has languished on the Minister’s desk for two months because Peru’s Ministry of Economy as well as Ministry of Foreign Commerce and Tourism have opposed the compulsory license.

Civil society groups continue to oppose the position of the Ministries of Economy and Commerce, and support the issuance of a compulsory license on atazanavir.

About the Kaletra Campaign

Information on Access Actions by Country

"Acting in concert around the world, we will fight pharmaceutical monopoly abuses".--Luz Marina Umbasia, attorney for Colombian treatment groups
"We are launching competition campaigns in many countries so we can work together for access"--Sindi Putri, ITPC Indonesia

About the Atazanavir Campaign

Access Story Spotlight

Peruvian civil society groups call on President Humala to issue a compulsory license on atazanavir, an important, second-line HIV medicine.   "I wish the drug company would lower the price, as I know that the number of people taking Kaletra is growing higher and higher – and there are many more who can’t afford the treatment they need." --Naza of Malaysia's PT Foundation 

Back to Public Citizen Global Access to Medicines Home Page

Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.